Billions of dollars are flowing into longevity biotechnology as scientists attempt to target the biological mechanisms of ageing. But researchers warn that altering such fundamental processes could create risks that science is only beginning to understand.

The desire to defeat ageing and overcome death is as old as human civilization. The search for immortality can be traced back to some of the earliest religious and literary traditions, including the Epic of Gilgamesh, in which Gilgamesh begins searching for eternal life after the death of his companion, Enkidu.

Thousands of years later, advances in genetic engineering, regenerative medicine and biotechnology have brought the question back into the spotlight: How far can science go in extending human life?

A conversation between Russian President Vladimir Putin and Chinese President Xi Jinping that was captured by a hot microphone also highlighted the growing interest in the subject. Putin referred to advances in organ transplantation, while Xi cited predictions that humans could live to as old as 150 this century. Russia has also reportedly directed billions of dollars toward organ transplantation and regenerative medicine research.

The rise of longevity biotechnology

Traditional pharmaceutical research has historically focused on developing chemical compounds that interact with specific biological targets. Biotechnology, by contrast, uses biological systems themselves to address medical and other challenges.

One of the most rapidly expanding areas of biotechnology is longevity biotechnology.

Its goal is not simply to make people live longer. Researchers are seeking to target the biological mechanisms that contribute to age-related diseases, with the aim of extending either healthspan, the period of life spent in good health, or overall lifespan.

The idea of intervening in ageing is not new. China's first emperor, Qin Shi Huang, is believed to have died after consuming mercury in his pursuit of an elixir of immortality. In the 1920s, Russian physician and scientist Alexander Bogdanov experimented with blood transfusions from younger people to older patients in an attempt to slow ageing, although there is little evidence that the approach worked.

What has changed in recent years is the scale of scientific and financial interest.

Scientists identify the hallmarks of ageing

Modern longevity research increasingly views ageing as a collection of interconnected biological processes.

Scientists have identified 12 major "hallmarks of ageing", including mechanisms such as genomic instability and chronic inflammation. Researchers have also identified genes that regulate many of these processes.

Manipulating some of these mechanisms in animal models has improved measures of health and physical function in older animals. In certain experiments, it has also extended lifespan.

The repetition of such findings across different research groups and animal models has helped drive growing interest among scientists and investors.

Investment reaches billions

Longevity biotechnology has become one of the newest areas attracting major investment.

In the first quarter of 2026 alone, longevity biotech companies reportedly raised approximately $3.74 billion. Academic journals dedicated to ageing and longevity have emerged, while pharmaceutical companies are closely watching clinical trials in the field.

The investment boom has been reinforced by developments elsewhere in science and medicine, particularly artificial intelligence and the extraordinary commercial success of modern obesity drugs.

What obesity drugs have taught investors

Obesity is a complex, multifactorial disease influenced by genetics, environment, living conditions and socioeconomic factors. For years, available treatments had significant limitations and generally produced modest results.

The arrival of highly effective modern obesity medicines changed expectations about what could be achieved pharmacologically.

Several obesity drugs have become among the world's best-selling medicines, demonstrating that major advances can emerge even in areas once considered extremely difficult to treat.

For investors, the comparison raises an obvious question: if science can make major progress against a complex condition such as obesity, could similar breakthroughs eventually be achieved in ageing?

The biological risks remain uncertain

Ageing, however, differs fundamentally from obesity.

It is a biological process experienced by virtually all humans and by most living organisms. The mechanisms associated with ageing are deeply embedded in systems responsible for immunity, reproduction, growth, metabolism and cellular maintenance.

Manipulating one of those systems could therefore have consequences elsewhere in the body.

Clinical trials in longevity biotechnology remain at relatively early stages, meaning scientists do not yet know the full range of long-term benefits or risks.

Another challenge is regulatory. The US Food and Drug Administration does not currently recognize ageing itself as a disease target. As a result, companies developing longevity interventions generally need to demonstrate benefits against specific diseases or measurable aspects of health.

DNA repair illustrates the challenge

One area of research involves manipulating DNA repair.

Human DNA is damaged continuously, and cells possess sophisticated mechanisms for repairing that damage. Those mechanisms can become less effective with age, making DNA repair an attractive potential target for longevity research.

But DNA repair is not simply a system that should be maximized without limits.

B cells, for example, deliberately introduce mutations into their DNA as part of the process of generating effective antibodies. If a therapy designed to improve DNA repair interfered with this process, it could potentially affect immune function.

The example illustrates a broader problem: biological systems are interconnected, and changing one mechanism can produce consequences somewhere else.

Extending life versus extending healthy life

Medicine has repeatedly demonstrated the trade-offs involved in manipulating biological processes.

Antibiotics can alter the microbiome and contribute to the selection of antibiotic-resistant bacteria. Chemotherapy can destroy healthy cells as well as cancer cells because many normal tissues also contain rapidly dividing cells.

Similar trade-offs could emerge with therapies designed to alter ageing.

Scientists may eventually develop interventions capable of slowing some aspects of biological ageing or extending healthy lifespan. But such treatments are unlikely to arrive quickly, and their long-term effects may take years or even decades to understand.

The central challenge for longevity biotechnology will be to intervene in ageing without significantly disrupting the biological balance between immunity, reproduction, growth, repair and maintenance.

The prospect of extending human lifespan is attracting unprecedented scientific and financial attention. Whether that ambition becomes a medical reality will ultimately depend not on investment alone, but on evidence from rigorous clinical research.